Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354115 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL27499 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7058506 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7056839 | 0.97 | ESR1 (0.94) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.95 | ESR1 (0.91) | ESR1ESR2 | |
| SCHEMBL6259524 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL28107129 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL2898159 | 0.92 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL21571869 | 0.91 | ESR1 (0.83) | ESR1ESR2 | |
| SCHEMBL6294980 | 0.90 | ESR1 (0.81) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165061-B1 | USE OF COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND PARTIAL ESTROGEN AGONISTS FOR TREATING OSTEOPOROSIS | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20190201526-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | WISTAR INST (US) | 2019-07-04 | — | — | US | disclosed |
| WO-2018049042-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY INHIBITING ESTROGEN SIGNALING IN MYELOID-DERIVED SUPPRESSOR CELLS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-03-15 | — | — | WO | disclosed |
| US-8835413-B2 | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | ENDORECHERCHE, INC. (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8389548-B2 | Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators | ENDORECHERCHE, INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8188066-B2 | Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators | ENDORECHERCHE, INC. (CA) | 2012-05-29 | — | — | US | disclosed |
| US-7943603-B2 | Medical treatment for conditions such as osteoporosis or breast cancer | ENDORECHERCHE, INC. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943603-B2 | Medical treatment for conditions such as osteoporosis or breast cancer | ENDORECHERCHE, INC. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7429576-B2 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070270394-A1 | Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | ENDORECHERCHE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070027122-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027123-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027124-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ENDORECHERCHE, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027124-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ESRRA, ESR2, ESRRG | ESR1 7/4885ESR2 2/4885 |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | ESR1 1993/4885ESR2 1524/4885 |
| US-20070270394-A1 | Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | PDE5A, PDE3A, PDE2A | ESR1 9/4885ESR2 18/4885 |
| US-20070027123-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ESRRA, ESR2, ESRRG | ESR1 7/4885ESR2 2/4885 |
| US-20190201526-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | ESRRG, ESR2, ESRRB | ESR1 6/4885ESR2 2/4885 |
| US-20070027122-A1 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | ESRRA, ESR2, ESRRG | ESR1 7/4885ESR2 2/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ESR1 3363/4885ESR2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.